Yes, there are questions...what, specifically, was the Adcom wording that dealt a material blow to Elite? Was there something said that indicated all current and future ADF opioids will no longer be allowed except for Inspirion's? What does that mean for Collegium, Acura, Purdue, Pfizer, Egalet, ICPI and all the others who did not get the memo?
Still, I am a bit confused. What is it that allows Inspirion to be so good they could monopolize the opioid pain med market? Cognizant as we are that the FTC would not allow a market monopoly. But even then, there is the issue of a growing multibillion dollar pain med market that affords few barriers to entry and no real market leader in ADFs. No, the argument about Inspirion holds no water and here is an example why...Gilead's HCV vaccine. Enough said.
Market Data 
Markets 
AI
